HS Does Not Stay the Same — It Follows a Pattern
Hidradenitis Suppurativa progresses in recognisable stages when the underlying drivers are not corrected. Understanding this progression — what changes, why, and at what pace — is the first step toward interrupting it. This page explains how HS evolves over time and what determines whether a case stabilises or worsens.
HS Is Not an Episodic Condition. It Is a Progressive One.
Many patients experience HS as a series of flares — boils that appear, discharge, settle, and return. This pattern can create the impression that the condition is unpredictable or cyclical. In reality, HS follows a largely predictable trajectory when internal drivers remain unaddressed.
Each flare is not a fresh event. It is a continuation of an underlying inflammatory and structural process that does not fully resolve between episodes. Over time, this process deepens — involving more tissue, creating scar formation, and eventually establishing permanent structural changes in the skin and surrounding layers.
Understanding how progression works is not meant to create alarm. It is meant to show why the same treatment that provided temporary relief in Stage 1 will not be sufficient by Stage 3 — and why earlier correction produces fundamentally different outcomes than later intervention.
"When a condition keeps recurring, it usually follows an underlying pattern that needs to be understood and addressed — not suppressed."
What Progression Actually Means
- Early lesions involve reversible inflammation — later lesions involve structural tissue change
- Scar tissue, once formed, permanently alters the local environment
- Sinus tracts are not individual lesions — they are a connected system within the tissue
- Systemic involvement (hormonal, metabolic, immune) intensifies as the condition matures
- The window for correction narrows as structural changes accumulate
- Suppression at one site does not prevent progression at adjacent or new sites
- Progression pace varies significantly by individual — hormonal and metabolic factors determine speed
How HS Changes as Internal Drivers Persist
These stages describe the clinical trajectory observed in HS cases where underlying systemic drivers remain uncorrected. The Hurley classification system describes structural severity; the stage descriptions below describe both the structural and systemic picture.
Occasional Nodules, Mild Inflammation
HS at this stage presents as isolated, painful nodules — often mistaken for boils or cysts. Each lesion typically resolves within days to weeks, though it may leave a small scar. The interval between episodes can be months. Internal inflammation is active but not yet structurally entrenched.
- Single or scattered lesions, one body area
- No sinus tracts or tunnels present
- Lesions resolve without permanent structural change
- Recurrence may be infrequent at first
- Often misdiagnosed as folliculitis or infected cyst
At this stage, internal correction produces the most complete outcomes. The inflammatory process has not yet embedded into tissue architecture.
Recurring Abscesses, Multiple Sites, Early Tunnelling
The same areas continue to be affected, and new areas may become involved. Episodes become more frequent. Early sinus tract formation begins — the tissue starts developing sub-surface channels connecting adjacent lesions. Discharge and odour become more pronounced during active phases.
- Multiple recurrences at the same sites
- Two or more body areas affected
- Early sinus tract formation — single tracts
- Intervals between flares shorten over time
- Increased discharge volume during active phases
This is the stage where most patients first seek specialist input — having tried antibiotics repeatedly without lasting relief. Internal drivers are active and sustained.
Continuous Drainage, Tunnelling, Fibrosis and Scarring
By Stage 3, the condition has become structurally embedded. Sinus tracts form interconnected networks beneath the skin surface. Continuous or near-continuous discharge is common. Fibrotic scarring — rope-like tissue across affected areas — develops. Mobility and function may be impaired in severe cases.
- Extensive, interconnected sinus tracts
- Continuous or persistent discharge
- Significant fibrotic scarring
- Widespread involvement — multiple body areas
- High impact on daily function and quality of life
Surgical excision may address specific lesion clusters but does not resolve the internal environment producing new lesions. Recurrence at excision margins is common without systemic correction.
Hormonal Disruption, Metabolic Involvement, Mental Health Impact
When HS has been active for years without root-cause correction, its effects extend beyond the skin. Chronic inflammation at this scale affects hormonal regulation, metabolic function, and — through its psychological burden — mental health. This stage represents a systemic condition, not merely a dermatological one.
- Worsening hormonal dysregulation (androgen excess, insulin resistance)
- Elevated systemic inflammatory markers
- Documented anxiety, depression, and social withdrawal
- Potential joint involvement in some cases
- Significant impact on intimate relationships and employment
Treatment at this stage requires addressing the full systemic picture — not just the skin. This is why isolated dermatological approaches consistently fail to provide durable relief at this severity level.
On the Hurley Classification: The standard Hurley staging system (I, II, III) classifies HS by structural severity — number of lesions, presence of sinus tracts, and degree of scarring. The four stages described above incorporate systemic involvement and are intended to complement, not replace, the Hurley framework. Hurley I broadly corresponds to Stage 1–early Stage 2; Hurley II to mid Stage 2–early Stage 3; Hurley III to advanced Stage 3 and beyond.
Hurley stage progression — how HS severity is clinically classified
HS Progresses When These Factors Remain Uncorrected
Structural progression in HS is not random. It is consistently linked to persistent internal imbalances that sustain the inflammatory and follicular environment in which the disease operates.
Sustained Gut Dysfunction
When digestive function is impaired, inflammatory load accumulates systemically. This provides a continuous substrate for immune dysregulation — the inflammation does not resolve between flares because its source has not been corrected.
Uncorrected Hormonal Imbalance
Androgen excess, insulin resistance, and disrupted cortisol patterns directly stimulate follicular activity in HS-prone regions. As long as these imbalances persist, the follicular environment remains susceptible — regardless of what surface treatments are applied.
Immune Dysregulation
In chronic HS, the immune response has been in a state of sustained activation for an extended period. This alters the immune system's calibration — responses become disproportionate, and the cycle of lesion formation becomes self-perpetuating at a biological level.
Repeated Suppression Without Correction
Courses of antibiotics, steroid injections, and surgical excision control active lesions — but do not address the tissue environment producing them. Each episode of suppression followed by recurrence contributes to progressive tissue change.
Lymphatic Stagnation
HS characteristically affects areas of lymphatic concentration — axilla, groin, perianal, inframammary. When lymphatic drainage is compromised, toxin accumulation is localised and persistent, maintaining the conditions for continued lesion activity.
Metabolic and Lifestyle Factors
Obesity, sedentary patterns, poor sleep, and high glycaemic load all independently sustain the inflammatory and hormonal environment that drives HS. These are not secondary factors — in many cases they are primary amplifiers of disease severity and progression pace.
Why HS Deepens Rather Than Resolves
At the core of HS progression is a feedback loop between internal inflammation and local tissue response. Each inflammatory episode leaves behind microscopic changes — altered follicular architecture, micro-scarring, modified immune signalling — that make the same site more susceptible to subsequent episodes.
The Tissue Memory Problem
Skin and subcutaneous tissue that has experienced repeated inflammation develops a form of cellular memory. The immune cells resident in that tissue become sensitised — they respond more readily, and more intensely, to stimuli that would previously have been tolerated. This is why HS lesions preferentially recur at the same locations, and why those locations tend to worsen over time while new sites begin to mirror the same pattern.
The Structural Entrenchment Problem
Sinus tracts are not simply channels in the skin — they are epithelialised structures lined with their own cellular environment. Once formed, they are not easily resolved through suppression alone. They represent a permanent structural change that sustains discharge and creates a reservoir for continued inflammatory activity. This is why Stage 3 cases require a fundamentally different approach than Stage 1.
The Systemic Amplification Problem
As HS persists, its effects on the wider hormonal and metabolic system become more pronounced. Elevated systemic inflammation affects insulin sensitivity, cortisol regulation, and androgen metabolism — all of which, in turn, feed back into the local disease environment. This is not a linear process; it is a progressively tightening cycle. HS is not a skin problem. It is a systemic inflammatory condition expressing through the skin.
Why Suppression Accelerates Progression
When suppression is applied without addressing the internal environment — antibiotics reduce bacterial load, steroids reduce acute inflammation, surgery removes tissue — the underlying drivers remain active. Between treatments, those drivers continue operating. The net result is that each treatment episode provides diminishing returns, while the structural and systemic picture continues to advance. Unless the underlying causes are addressed, the condition may continue to recur despite treatment.
Disease progression timeline — how HS evolves when internal drivers remain unaddressed
Progression Is Not Inevitable — But Correction Must Be Systematic
The same mechanisms that drive progression when uncorrected can be interrupted when addressed systematically. The goal is not to manage each flare in isolation — it is to change the internal environment so that flares become progressively less frequent, less severe, and ultimately absent.
This requires addressing each layer of the disease simultaneously — not sequentially applying treatments that each target one dimension while leaving others active.
-
01
Gut and inflammatory load correction Reducing the systemic inflammatory substrate removes the fuel that sustains follicular and immune dysregulation between flares.
-
02
Hormonal and metabolic stabilisation Correcting androgen excess, insulin resistance, and related endocrine imbalances directly reduces the follicular stimulus in HS-prone regions.
-
03
Tissue repair support Structured formulations that support tissue integrity, reduce fibrotic progression, and assist lymphatic drainage address the structural dimension of the disease.
-
04
Recurrence prevention Stabilising immunity and lifestyle factors creates the conditions under which the corrected internal environment is maintained long-term.
Understanding Your Stage Is the Starting Point
Progression in HS is not a fixed outcome. The internal drivers that sustain it can be identified and corrected through a structured, personalised approach. A clinical evaluation identifies where in the progression pattern your case currently sits — and what a systematic correction looks like for your specific presentation.